Clinical effects of intravenous iloprost in patients with intermittent claudication.
In a randomized patient-blind study iloprost or hydroxy-ethyl starch 200/0.5 were given i.v. 5 h daily for 2 weeks to 24 patients suffering from severe intermittent claudication due to peripheral vascular disease. An increase in pain-free walking distance of more than 50% occurred in 6 of 11 patients after the iloprost infusions and in 7 of 12 patients after HES treatment. No significant effects on haemodynamic or clinical chemistry tests were observed.
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001157:Arterial Occlusive Diseases / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D001809:Blood Viscosity / Q000187:drug effects; D011464:Epoprostenol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004903:Erythrocyte Aggregation / Q000187:drug effects; D006801:Humans; D016285:Iloprost; D007262:Infusions, Intravenous; D007383:Intermittent Claudication / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D010991:Plethysmography
D000889:Anti-Arrhythmia Agents; D011464:Epoprostenol; D016285:Iloprost